✦ LIBER ✦
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features
✍ Scribed by Nicolino Ruperto; Pierre Quartier; Nico Wulffraat; Patricia Woo; Angelo Ravelli; Richard Mouy; Brigitte Bader-Meunier; Sebastiaan J. Vastert; Emanuele Noseda; Daniele D'Ambrosio; Jean Lecot; Abhijit Chakraborty; Alberto Martini; Andrea Chioato; Paediatric Rheumatology International Clinical Trials Organisation
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 311 KB
- Volume
- 64
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.